CTP-Modified Polypeptides for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polypeptides have short circulatory half-lives due to susceptibility to denaturation and enzymatic degradation, leading to unfavorable pharmacokinetics and frequent dosing requirements, which can result in discomfort and reduced therapeutic efficacy.
Innovation Solution
Modification of polypeptides with carboxy-terminal peptides (CTPs) of chorionic gonadotropin, attached to both the amino and carboxy termini of growth hormone, to enhance stability and prolong half-life, reducing dosing frequency while maintaining pharmacological efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptides are administered frequently to maintain therapeutic levels, then pharmacological efficacy is maintained, but patient comfort deteriorates and dosing complexity increases
Solution Approach 1:
The patent applies dynamics by modifying the polypeptide structure to change its pharmacokinetic properties. Specifically, attaching carboxy-terminal peptides (CTPs) of chorionic gonadotropin to the polypeptide of interest alters its circulation dynamics, extending half-life from several hours to potentially weekly intervals, thereby reducing dosing frequency while maintaining therapeutic efficacy
Solution Approach 2:
The patent changes the molecular parameters of the polypeptide by attaching CTP moieties. This structural modification changes the pharmacokinetic parameters including serum half-life, clearance rate, and dosing interval. The CTP attachment transforms the polypeptide from short-acting to long-acting, resolving the contradiction between maintaining efficacy and improving patient comfort
2Duration of action of stationary object
If polypeptide molecular weight is increased to prolong half-life, then serum stability improves, but renal clearance increases and therapeutic levels become unfeasible
Solution Approach 1:
The patent carefully controls the molecular weight increase through selective attachment of CTP moieties. The CTP attachment increases molecular weight enough to prolong half-life by protecting against enzymatic degradation, but not so much that renal filtration becomes excessive. This optimized parameter change resolves the contradiction between extending duration and maintaining therapeutic feasibility
Solution Approach 2:
The patent creates a composite polypeptide structure combining the polypeptide of interest with CTP moieties of chorionic gonadotropin. This composite structure leverages the protective effects of the CTP against enzymatic degradation while maintaining a molecular weight that avoids excessive renal clearance, thus resolving the contradiction between extended half-life and therapeutic level maintenance
3Reliability
If polypeptides are administered by infusion to maintain therapeutic levels, then pharmacological efficacy is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
The patent transforms the administration regimen from frequent infusions to less frequent injections by modifying the polypeptide's pharmacokinetic dynamics. The CTP-modified polypeptide maintains therapeutic levels over extended periods, converting a complex multi-dose infusion protocol into a simpler single-dose or less frequent injection regimen, thereby reducing treatment complexity while maintaining efficacy
Data Source
AI summary
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.